Cardiovascular risk profile in patients with spondyloarthritis

Joint Bone Spine

Volumn 81, Issue 1, 2014, Pages 57-63

  Papagoras, Charalampos ^a   Markatseli, Theodora E ^a   Saougou, Ioanna ^a   Alamanos, Yannis ^b   Zikou, Anastasia K ^c   Voulgari, Paraskevi V ^a   Kiortsis, Dimitrios N ^a   Drosos, Alexandros A ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

^c University of Patras ^*  (Greece)

Author keywords

Ankylosing spondylitis; Apolipoprotein; Atherogenic index; Cholesterol; Psoriatic arthritis; Spondyloarthritis

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN E; CYCLOSPORIN A; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEFLUNOMIDE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; PREDNISONE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; URATE; HIGH DENSITY LIPOPROTEIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ABDOMINAL FAT; ABDOMINAL OBESITY; ADULT; ANKYLOSING SPONDYLITIS; ARTERIAL WALL THICKNESS; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; CARDIOVASCULAR RISK; CAROTID ARTERY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DAS28; DISEASE ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; FAMILY HISTORY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; OBESITY; PSORIATIC ARTHRITIS; SMOKING; SPONDYLARTHRITIS; URIC ACID BLOOD LEVEL; WAIST HIP RATIO; ATHEROGENIC INDEX; CARDIOVASCULAR DISEASE ASSESSMENT; GREECE; LIPOPROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; ARTHRITIS, PSORIATIC; CARDIOVASCULAR DISEASES; RISK FACTOR; SPONDYLITIS, ANKYLOSING;

ADULT; ARTHRITIS, PSORIATIC; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RISK FACTORS; SPONDYLARTHRITIS; SPONDYLITIS, ANKYLOSING;

EID: 84893710605     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2013.03.019     Document Type: Article

References (40)

1. Baeten D., Breban M., Lories R., et al. Are spondylarthritides related but distinct conditions or a single disease with a heterogeneous phenotype?. Arthritis Rheum 2013, 65:12-20.
2. Peters M.J., Symmons D.P., McCarey D., et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010, 69:325-331.
3. Prati C., Claudepierre P., Pham T., et al. Mortality in spondylarthritis. Joint Bone Spine 2011, 78:466-470.
4. Papagoras C., Voulgari P.V., Drosos A.A. Atherosclerosis and cardiovascular disease in the spondyloarthritides, particularly ankylosing spondylitis and psoriatic arthritis. Clin Exp Rheumatol 2013, [Epub ahead of print].
5. Han C., Robinson D.W., Hackett M.V., et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006, 33:2167-2172.
6. Mathieu S., Gossec L., Dougados M., et al. Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2011, 63:557-563.
7. Szabo S.M., Levy A.R., Rao S.R., et al. Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: a population-based study. Arthritis Rheum 2011, 63:3294-3304.
8. Bremander A., Petersson I.F., Bergman S., et al. Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res (Hoboken) 2011, 63:550-556.
9. Gladman D.D., Ang M., Su L., et al. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 2009, 68:1131-1135.
10. Mok C.C., Ko G.T., Ho L.Y., et al. Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res (Hoboken) 2011, 63:195-202.
11. Jones S.M., Harris C.P., Lloyd J., et al. Lipoproteins and their subfractions in psoriatic arthritis: identification of an atherogenic profile with active joint disease. Ann Rheum Dis 2000, 59:904-909.
12. Kimhi O., Caspi D., Bornstein N.M., et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 2007, 36:203-209.
13. Gonzalez-Juanatey C., Llorca J., Amigo-Diaz E., et al. High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007, 57:1074-1080.
14. Tam L.S., Tomlinson B., Chu T.T., et al. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls-the role of inflammation. Rheumatology (Oxford) 2008, 47:718-723.
15. Eder L., Zisman D., Barzilai M., et al. Subclinical atherosclerosis in psoriatic arthritis: a case-control study. J Rheumatol 2008, 35:877-882.
16. Gonzalez-Juanatey C., Llorca J., Miranda-Filloy J.A., et al. Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007, 57:287-293.
17. Dougados M., van der Linden S., Juhlin R., et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991, 34:1218-1227.
18. van der Linden S., Valkenburg H.A., Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984, 27:361-368.
19. Taylor W., Gladman D., Helliwell P., et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006, 54:2665-2673.
20. Vardavas C.I., Kafatos A.G. Smoking policy and prevalence in Greece: an overview. Eur J Public Health 2007, 17:211-213.
21. Kaan U., Ferda O. Evaluation of clinical activity and functional impairment in smokers with ankylosing spondylitis. Rheumatol Int 2005, 25:357-360.
22. Ward M.M., Hendrey M.R., Malley J.D., et al. Clinical and immunogenetic prognostic factors for radiographic severity in ankylosing spondylitis. Arthritis Rheum 2009, 61:859-866.
23. Poddubnyy D., Haibel H., Listing J., et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum 2012, 64:1388-1398.
24. Chung H.Y., Machado P., van der Heijde D., et al. Smokers in early axial spondyloarthritis have earlier disease onset, more disease activity, inflammation and damage, and poorer function and health-related quality of life: results from the DESIR cohort. Ann Rheum Dis 2012, 71:809-816.
25. Eder L., Shanmugarajah S., Thavaneswaran A., et al. The association between smoking and the development of psoriatic arthritis among psoriasis patients. Ann Rheum Dis 2012, 71:219-224.
26. Li W., Han J., Qureshi A.A. Smoking and risk of incident psoriatic arthritis in US women. Ann Rheum Dis 2012, 71:804-808.
27. Li W., Han J., Qureshi A.A. Obesity and risk of incident psoriatic arthritis in US women. Ann Rheum Dis 2012, 71:1267-1272.
28. Love T.J., Zhu Y., Zhang Y., et al. Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis 2012, 71:1273-1277.
29. Khovidhunkit W., Memon R.A., Feingold K.R., et al. Infection and inflammation-induced proatherogenic changes of lipoproteins. J Infect Dis 2000, 181:S462-S472.
30. Toms T.E., Panoulas V.F., Kitas G.D. Dyslipidaemia in rheumatological autoimmune diseases. Open Cardiovasc Med J 2011, 5:64-75.
31. Liberopoulos E., Miltiadous G., Hatzivassiliou M., et al. polymorphism in northwestern Greece: frequency and effect on lipid parameters. Ann Clin Lab Sci 2004, 34:347-354.
32. Gaffo A.L., Jacobs D.R., Sijtsma F., et al. Serum urate association with hypertension in young adults: analysis from the Coronary Artery Risk Development in Young Adults cohort. Ann Rheum Dis 2012, [Epub ahead of print].
33. Strasak A.M., Kelleher C.C., Brant L.J., et al. Serum uric acid is an independent predictor for all major forms of cardiovascular death in 28,613 elderly women: a prospective 21-year follow-up study. Int J Cardiol 2008, 125:232-239.
34. Gonzalez-Gay M.A., Gonzalez-Juanatey C., Vazquez-Rodriguez T.R., et al. Asymptomatic hyperuricemia and serum uric acid concentration correlate with subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease. Semin Arthritis Rheum 2009, 39:157-162.
35. Mathieu S., Joly H., Baron G., et al. Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease. Rheumatology (Oxford) 2008, 47:1203-1207.
36. van Eijk I.C., de Vries M.K., Levels J.H., et al. Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis. Arthritis Rheum 2009, 60:1324-1330.
37. Kiortsis D.N., Mavridis A.K., Filippatos T.D., et al. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 2006, 33:921-923.
38. Mathieu S., Dubost J.J., Tournadre A., et al. Effects of 14 weeks of TNF alpha blockade treatment on lipid profile in ankylosing spondylitis. Joint Bone Spine 2010, 77:50-52.
39. Channual J., Wu J.J., Dann F.J. Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis. Dermatol Ther 2009, 22:61-73.
40. Daïen C.I., Duny Y., Barnetche T., et al. Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. Ann Rheum Dis 2012, 71:862-868.